<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77300">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01965145</url>
  </required_header>
  <id_info>
    <org_study_id>CL3-78989-002</org_study_id>
    <secondary_id>2012-001125-27</secondary_id>
    <secondary_id>U1111-1135-1411</secondary_id>
    <nct_id>NCT01965145</nct_id>
  </id_info>
  <brief_title>Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)</brief_title>
  <acronym>EYEGUARD™-B</acronym>
  <official_title>A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate the superiority of gevokizumab as compared to
      placebo on top of current standard of care in reducing the risk of Behçet's disease uveitis
      exacerbations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the
      treatment of patients with Behçet's disease uveitis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to first acute ocular exacerbation</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Behcet's Uveitis</condition>
  <arm_group>
    <arm_group_label>Gevokizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for subcutaneous injection, Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution for subcutaneous injection, placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gevokizumab</intervention_name>
    <description>Sterile solution administered subcutaneously</description>
    <arm_group_label>Gevokizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile solution administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Behçet's disease diagnosis fulfilling the International Study Group Classification
             Criteria.

          -  History of Behçet's disease uveitis with ocular involvement of the posterior segment.

          -  Patients with a stable background treatment of oral corticosteroid and at least one
             immunosuppressive drug.

          -  Male or female, age ≥18 (or legal age of majority in the country) at selection

          -  For subjects with reproductive potential, a willingness to use highly effective
             contraceptive measures

        Exclusion Criteria:

          -  Infectious uveitis, uveitis due to causes other than Behçet's disease.

          -  Monocular vision

          -  Presence of severe cataract or severe posterior capsular opacification.

          -  Contraindication to mydriasis or presence of posterior synechiae.

          -  Active TB disease.

          -  History of severe allergic or anaphylactic reactions to monoclonal antibodies

          -  History of malignancy within 5 years prior to Selection.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung Chul LEE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>IRIS</last_name>
    <email>clinicaltrials@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 17, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Chorioretinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
